EMA Withdrawn: Viekirax (ombitasvir;paritaprevir;ritonavir) — AbbVie Deutschland GmbH & Co. KG

View source ↗

Summary

The EMA has withdrawn the marketing authorization for Viekirax (ombitasvir/paritaprevir/ritonavir) for chronic hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Viekirax (ombitasvir/paritaprevir/ritonavir)

Snippet

Status: Withdrawn. Therapeutic area: Hepatitis C, Chronic. MAH: AbbVie Deutschland GmbH & Co. KG. Decision date: 12/08/2022